Aclaris Therapeutics, Inc. (ACRS)
6.375
+0.06
(+1.03%)
USD |
NASDAQ |
Aug 25, 09:45
Aclaris Therapeutics Enterprise Value : 792.59M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 792.59M |
| August 21, 2026 | 806.57M |
| August 20, 2026 | 795.38M |
| August 19, 2026 | 810.76M |
| August 18, 2026 | 791.89M |
| August 17, 2026 | 738.05M |
| August 14, 2026 | 718.48M |
| August 13, 2026 | 729.66M |
| August 12, 2026 | 726.87M |
| August 11, 2026 | 738.05M |
| August 10, 2026 | 735.26M |
| August 07, 2026 | 736.66M |
| August 06, 2026 | 761.82M |
| August 05, 2026 | 799.58M |
| August 04, 2026 | 746.44M |
| August 03, 2026 | 683.52M |
| July 31, 2026 | 637.38M |
| July 30, 2026 | 654.16M |
| July 29, 2026 | 626.19M |
| July 28, 2026 | 655.56M |
| July 27, 2026 | 661.15M |
| July 24, 2026 | 641.58M |
| July 23, 2026 | 676.53M |
| July 22, 2026 | 696.11M |
| July 21, 2026 | 705.89M |
| Date | Value |
|---|---|
| July 20, 2026 | 689.12M |
| July 17, 2026 | 704.50M |
| July 16, 2026 | 659.75M |
| July 15, 2026 | 693.31M |
| July 14, 2026 | 669.54M |
| July 13, 2026 | 679.33M |
| July 10, 2026 | 690.51M |
| July 09, 2026 | 708.69M |
| July 08, 2026 | 680.73M |
| July 07, 2026 | 696.11M |
| July 06, 2026 | 677.93M |
| July 02, 2026 | 687.72M |
| July 01, 2026 | 656.96M |
| June 30, 2026 | 649.96M |
| June 29, 2026 | 597.63M |
| June 26, 2026 | 594.83M |
| June 25, 2026 | 582.26M |
| June 24, 2026 | 565.51M |
| June 23, 2026 | 583.66M |
| June 22, 2026 | 572.49M |
| June 18, 2026 | 525.01M |
| June 17, 2026 | 513.83M |
| June 16, 2026 | 502.66M |
| June 15, 2026 | 505.46M |
| June 12, 2026 | 499.87M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Corcept Therapeutics, Inc. | 13.00B |
| Nektar Therapeutics | 1.967B |
| Xeris Biopharma Holdings, Inc. | 1.685B |
| Crinetics Pharmaceuticals, Inc. | 7.812B |
| Alumis, Inc. | 2.494B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -21.50M |
| Revenue (Quarterly) | 1.629M |
| Total Expenses (Quarterly) | 23.13M |
| EPS Diluted (Quarterly) | -0.1507 |
| Gross Profit Margin (Quarterly) | 10.80% |
| Profit Margin (Quarterly) | -1.32K% |
| Earnings Yield | -9.18% |
| Normalized Earnings Yield | -9.111 |